Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.068,41
-1,05%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ HUTCHMED China Limited (HCM) HUTCHMED China Limited (HCM) Notizie

HUTCHMED China Limited

HCM
18,675
-0,315 (-1,66%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/4/202414:30GLOBEHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in..
05/4/202410:30GLOBEHUTCHMED Highlights Data to be Presented at..
02/4/202406:30GLOBEHUTCHMED and Innovent Jointly Announce NDA Acceptance in..
28/3/202401:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
22/3/202401:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
05/3/202412:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:40EDGAR2Form 20-F - Annual and transition report of foreign private..
28/2/202412:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
07/2/202412:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202401:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02/2/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202409:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202409:30GLOBEHUTCHMED to Announce 2023 Final Results
30/1/202412:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202405:53GLOBEHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval..
11/1/202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202408:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
11/1/202401:00GLOBEHUTCHMED Announces NDA Acceptance in China for Sovleplenib..
29/12/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202312:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202308:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
13/12/202305:30GLOBEHUTCHMED Announces Continued Inclusion of ELUNATE®..
13/12/202301:00GLOBEHUTCHMED Announces that it has Completed Enrollment of a..
07/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202308:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
01/12/202301:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at 2023..
30/11/202312:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/11/202314:35GLOBEDeutsche Bank ADR Investor Conference: Presentations Now..
09/11/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/11/202301:11GLOBEHUTCHMED Announces that Takeda Receives U.S. FDA Approval of..
01/11/202313:35GLOBEInternational companies to host live webcasts at Deutsche..
24/10/202312:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202310:30GLOBEHUTCHMED Highlights Clinical Data to be Presented at..
29/9/202312:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/9/202310:30GLOBEHUTCHMED Announces Submission of New Drug Application for..
14/9/202312:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202310:30GLOBEHUTCHMED Highlights Presentation of Results from the Phase..
12/9/202308:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
12/9/202302:00GLOBEHUTCHMED Completes Patient Enrollment of a Bridging Study of..
31/8/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202312:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202308:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
29/8/202302:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
21/8/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 18,99 Min: 17,46 Max: 18,99
Chiusura: 18,99

La tua Cronologia

NASDAQ
HCM
HUTCHMED China
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network